Largest pharmaceutical companies by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Johnson & Johnson leads the 52 pharmaceutical companies ranked by revenue, at SAR 353.3B, ahead of Eli Lilly (SAR 244.5B) and Merck & Co (SAR 243.9B). Figures as of 18 Nov 2026, 18:13 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 52
- First
- Johnson & JohnsonSAR 353.3B
- Median
- SAR 12B
- Combined market value
- SAR 19.09T
- Countries
- 10
- Not ranked
- 9no revenue on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Revenue ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Johnson & JohnsonJNJ · Health Care | SAR 353.3B | SAR 2.49T | SAR 1,033.89 | 1.10% down | 38% up | ||
| 2 | Eli LillyLLY · Health Care | SAR 244.5B | SAR 4.65T | SAR 5,222.32 | 1.65% down | 35% up | ||
| 3 | Merck & CoMRK · Health Care | SAR 243.9B | SAR 1.28T | SAR 520.00 | 3.31% down | 51% up | ||
| 4 | PfizerPFE · Health Care | SAR 234.7B | SAR 602.4B | SAR 105.69 | 1.03% down | 14% up | ||
| 5 | AbbVieABBV · Health Care | SAR 229.4B | SAR 1.91T | SAR 1,080.66 | 1.61% down | 26% up | ||
| 6 | AstraZenecaAZN · Health Care | SAR 220.3B | SAR 1.05T | SAR 673.84 | 1.44% down | 2% up | ||
| 7 | NovartisNVS · Health Care | SAR 204.5B | SAR 1.11T | SAR 585.10 | 1.98% down | 25% up | ||
| 8 | SanofiSNY · Health Care | SAR 181.6B | SAR 426.3B | SAR 177.53 | 0.42% down | 4% down | ||
| 9 | Bristol-Myers SquibbBMY · Health Care | SAR 180.8B | SAR 460.9B | SAR 225.47 | 2.02% down | 34% up | ||
| 10 | Novo NordiskNVO · Health Care | SAR 172B | SAR 654.7B | SAR 148.56 | 2.69% down | 17% down | ||
| 11 | Abbott LaboratoriesABT · Health Care | SAR 166.3B | SAR 680.2B | SAR 392.73 | 0.01% down | 17% down | ||
| 12 | GSKGSK · Health Care | SAR 162.6B | SAR 367B | SAR 183.09 | 0.87% down | 6% up | ||
| 13 | Takeda PharmaceuticalTAK · Health Care | SAR 105.8B | SAR 256.3B | SAR 80.23 | 1.16% down | 54% up | ||
| 14 | Teva Pharmaceutical IndustriesTEVA · Health Care | SAR 64.7B | SAR 184.3B | SAR 157.92 | 1.22% down | 74% up | ||
| 15 | Regeneron PharmaceuticalsREGN · Health Care | SAR 53.8B | SAR 367.4B | SAR 3,551.39 | 1.15% down | 36% up | ||
| 16 | ViatrisVTRS · Health Care | SAR 53.6B | SAR 88.8B | SAR 77.44 | 0.95% up | 96% up | ||
| 17 | Vertex PharmaceuticalsVRTX · Health Care | SAR 45B | SAR 510.9B | SAR 2,015.19 | 0.57% up | 27% up | ||
| 18 | ZoetisZTS · Health Care | SAR 35.5B | SAR 129.6B | SAR 318.95 | 1.86% up | 29% down | ||
| 19 | GrifolsGRFS · Health Care | SAR 31.3B | SAR 21.6B | SAR 31.74 | 1.96% down | 1% up | ||
| 20 | BeOne MedicinesONC · Health Care | SAR 20B | SAR 173.7B | SAR 1,520.92 | 1.89% down | 17% up | ||
| 21 | Elanco Animal HealthELAN · Health Care | SAR 17.7B | SAR 50.5B | SAR 100.96 | 4.12% up | 20% up | ||
| 22 | Jazz PharmaceuticalsJAZZ · Health Care | SAR 16B | SAR 59.4B | SAR 925.00 | 2.45% up | 37% up | ||
| 23 | GenmabGMAB · Health Care | SAR 14B | SAR 119.1B | SAR 193.23 | 0.86% down | 70% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | SAR 13.9B | SAR 76B | SAR 567.06 | 3.40% down | 66% down | ||
| 25 | Dr. Reddy's LaboratoriesRDY · Health Care | SAR 13.4B | SAR 47B | SAR 56.37 | 1.61% up | 5% up | ||
| 26 | BioMarin PharmaceuticalBMRN · Health Care | SAR 12.1B | SAR 44.1B | SAR 227.50 | 3.66% up | 11% up | ||
| 27 | United TherapeuticsUTHR · Health Care | SAR 11.9B | SAR 93B | SAR 2,184.77 | 0.28% down | 23% up | ||
| 28 | Amneal PharmaceuticalsAMRX · Health Care | SAR 11.3B | SAR 28.8B | SAR 82.60 | 4.26% up | 83% up | ||
| 29 | Royalty PharmaRPRX · Health Care | SAR 8.9B | SAR 149.6B | SAR 260.09 | 0.96% up | 78% up | ||
| 30 | PTC TherapeuticsPTCT · Health Care | SAR 6.5B | SAR 18.9B | SAR 226.30 | 0.05% down | 20% down | ||
| 31 | AlkermesALKS · Health Care | SAR 5.5B | SAR 29.6B | SAR 176.07 | 3.28% up | 58% up | ||
| 32 | Legend BiotechLEGN · Health Care | SAR 3.9B | SAR 11.8B | SAR 60.95 | 0.87% up | 42% down | ||
| 33 | Madrigal PharmaceuticalsMDGL · Health Care | SAR 3.6B | SAR 35.5B | SAR 1,528.65 | 3.43% down | 24% down | ||
| 34 | Ionis PharmaceuticalsIONS · Health Care | SAR 3.5B | SAR 17.2B | SAR 103.17 | 2.02% up | 64% down | ||
| 35 | Arrowhead PharmaceuticalsARWR · Health Care | SAR 3.1B | SAR 23.1B | SAR 163.09 | 1.14% up | 10% up | ||
| 36 | Ascendis PharmaASND · Health Care | SAR 3B | SAR 66.8B | SAR 1,018.85 | 0.16% up | 28% up | ||
| 37 | Corcept TherapeuticsCORT · Health Care | SAR 2.9B | SAR 28B | SAR 255.84 | 2.66% down | 8% down | ||
| 38 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | SAR 2.5B | SAR 28B | SAR 356.04 | 0.20% down | 126% up | ||
| 39 | Axsome TherapeuticsAXSM · Health Care | SAR 2.4B | SAR 26.5B | SAR 502.90 | 1.38% down | 7% down | ||
| 40 | TG TherapeuticsTGTX · Health Care | SAR 2.3B | SAR 37.4B | SAR 247.45 | 5.20% up | 107% up | ||
| 41 | InsmedINSM · Health Care | SAR 2.3B | SAR 99.3B | SAR 452.75 | 0.95% down | 40% down | ||
| 42 | Mirum PharmaceuticalsMIRM · Health Care | SAR 2B | SAR 22.7B | SAR 347.12 | 0.64% up | 31% up | ||
| 43 | BridgeBio PharmaBBIO · Health Care | SAR 1.9B | SAR 57B | SAR 292.77 | 1.63% up | 17% up | ||
| 44 | Travere TherapeuticsTVTX · Health Care | SAR 1.8B | SAR 18.4B | SAR 191.60 | 0.04% down | 44% up | ||
| 45 | Ligand PharmaceuticalsLGND · Health Care | SAR 1B | SAR 22.5B | SAR 1,126.54 | 2.22% up | 43% up | ||
| 46 | Rhythm PharmaceuticalsRYTM · Health Care | SAR 711.8M | SAR 30.9B | SAR 445.04 | 1.75% up | 13% up | ||
| 47 | CytokineticsCYTK · Health Care | SAR 330.2M | SAR 26.9B | SAR 193.42 | 0.16% down | 20% down | ||
| 48 | Protagonist TherapeuticsPTGX · Health Care | SAR 172.6M | SAR 30.7B | SAR 470.94 | 0.71% up | 46% up | ||
| 49 | Roivant SciencesROIV · Health Care | SAR 31M | SAR 104.7B | SAR 144.56 | 0.44% down | 90% up | ||
| 50 | Dianthus TherapeuticsDNTH · Health Care | SAR 7.6M | SAR 18.4B | SAR 326.19 | 0.02% down | 113% up | ||
| 51 | Spyre TherapeuticsSYRE · Health Care | SAR 0 | SAR 34.4B | SAR 362.59 | 3.04% up | 286% up | ||
| 52 | Praxis Precision MedicinesPRAX · Health Care | SAR 0 | SAR 32.3B | SAR 1,154.00 | 0.85% up | 61% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7510 SAR). 9 companies have no revenue on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by revenue?
Johnson & Johnson (SAR 353.3B), Eli Lilly (SAR 244.5B) and Merck & Co (SAR 243.9B) are the top three of the 52 pharmaceutical companies ranked by revenue as of 18 Nov 2026, 18:13 UTC.
How many pharmaceutical companies are in this ranking?
52 are ranked by revenue. 9 more have no revenue on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 52 pharmaceutical companies ranked by revenue have a combined market value of SAR 19.09T as of 18 Nov 2026, 18:13 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest pharmaceutical companies by revenue”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.